[Increasing consumption of dietary fiber complementary to the treatment of metabolic syndrome]. / Incremento en el consumo de fibra dietética complementario al tratamiento del síndrome metabólico.

INTRODUCTION: the amount of fiber ingested in Latin American countries is lower (10-20 g/d) than recommended (35 g/d). An increase isrecommended for patients with metabolic syndrome (MS) to reduce cardiovascular risk, as well as to prevent obesity and other complications. OBJECTIVE: to evaluate whether increased dietary fiber consumption complements MS treatment and improves clinical and laboratory parameters in subjects at the San Martín Mexicapam "La Joya" Health Center, Oaxaca (Mexico). METHODS: an analytical-longitudinal study was carried out from January to April 2017, to evaluate nutritional status before and after intervention with dietary fiber and to measure cholesterol levels, triglycerides and fasting blood glucose. An increase of 15 g of fiber (fruits-vegetables and/or oat bran and/or wheat bran) was indicated in the usual diet over eight weeks. RESULTS: the sample consisted of 30 participants from the Mutual Aid Group diagnosed with MS, with an average age of 37.26 years, starting from a body mass index (BMI) of 30.75 kg/cm2 and levels of fasting glycemia at 153.87 mg/dl, triglycerides at 209.67 mg/dl, and cholesterol at 213.81 mg/dl. Following the intervention, a statistically significant difference (p < 0.05) was obtained with a BMI of 29.7 kg/cm2, fasting glycemia at 127.77 mg/dl, triglycerides at 179.71 mg/dl and cholesterol at 207.13 mg/dl. CONCLUSION: a reduction in the results for the parameters tested in patients of MS is improved by a greater consumption of dietary fiber, such as oat bran. However, additional studies are required to generate clearer recommendations.

Incremento en el consumo de fibra dietética complementario al tratamiento del síndrome metabólico / Increasing consumption of dietary fiber complementary to the treatment of metabolic síndrome

Introducción: la fibra ingerida por la población en Latinoamérica es inferior (10-20 g/d) a lo recomendado por la Organización Mundial de la Salud (OMS) (25-35 g/d). Su consumo se debe promover para pacientes con síndrome metabólico (SM), ya que reduce el riesgo cardiovascular y previene la obesidad y alteraciones asociadas. Objetivo: evaluar si el incremento del consumo de fibra dietética como coadyuvante para el tratamiento de SM en sujetos del Centro de Salud de San Martín Mexicapam "La Joya", Oaxaca (México), mejora los parámetros clínicos y laboratoriales de los mismos. Métodos: se trató de un estudio analítico-longitudinal llevado a cabo desde enero hasta abril de 2017, en el cual se evaluó el estado nutricional antes y después de la intervención con fibra dietética y se midieron los niveles de colesterol, triglicéridos y glucosa en sangre en ayuno. Se indicó un incremento de 15 g de fibra (frutas-verduras y/o salvado de avena y/o salvado de trigo) a la dieta habitual por un lapso continuo de ocho semanas. Resultados: la muestra fue de 30 participantes del Grupo de Ayuda Mutua diagnosticados con SM, cuya media de edad fue de 37,26 años y con un índice de masa corporal (IMC) al inicio de 30,75 kg/cm2, glucemia de ayuno de 153,87 mg/dl, triglicéridos de 209,67 mg/dl y colesterol de 213,81 mg/dl. Al finalizar la intervención se obtuvo una diferencia estadísticamente significativa (p < 0,05): IMC de 29,7 kg/cm2, glucemia de ayuno de 127,77 mg/dl, triglicéridos de 179,71 mg/dl y colesterol de 207,13 mg/dl. Conclusión: el incremento del consumo de fibra dietética (salvado de avena) funciona como complemento al tratamiento del SM para disminuir los parámetros clínicos y laboratoriales de los sujetos de estudio. Sin embargo, se requiere de más estudios para generar recomendaciones más claras

Introduction: the amount of fiber ingested in Latin American countries is lower (10-20 g/d) than recommended (35 g/d). An increase is recommended for patients with metabolic syndrome (MS) to reduce cardiovascular risk, as well as to prevent obesity and other complications. Objective: to evaluate whether increased dietary fiber consumption complements MS treatment and improves clinical and laboratory parameters in subjects at the San Martin Mexicapam "La Joya" Health Center, Oaxaca (Mexico). Methods: an analytical-longitudinal study was carried out from January to April 2017, to evaluate nutritional status before and after intervention with dietary fiber and to measure cholesterol levels, triglycerides and fasting blood glucose. An increase of 15 g of fiber (fruits-vegetables and/ or oat bran and/or wheat bran) was indicated in the usual diet over eight weeks. Results: the sample consisted of 30 participants from the Mutual Aid Group diagnosed with MS, with an average age of 37.26 years, starting from a body mass index (BMI) of 30.75 kg/cm2 and levels of fasting glycemia at 153.87 mg/dl, triglycerides at 209.67 mg/dl, and cholesterol at 213.81 mg/dl. Following the intervention, a statistically significant difference (p < 0.05) was obtained with a BMI of 29.7 kg/cm2, fasting glycemia at 127.77 mg/dl, triglycerides at 179.71 mg/dl and cholesterol at 207.13 mg/dl. Conclusion: a reduction in the results for the parameters tested in patients of MS is improved by a greater consumption of dietary fiber, such as oat bran. However, additional studies are required to generate clearer recommendations